BioCentury | Aug 22, 2013
Targets & Mechanisms

Tamping down TAU

...when massive and irreversible brain damage and spreading have already occurred. Morten Albrechtsen, CEO at Enkam Pharmaceuticals A/S...
...determining whether they will be effective at preventing disease, stopping its progression or curing patients. Enkam...
...Institutions Mentioned BioArctic Neuroscience AB , Stockholm, Sweden Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Enkam Pharmaceuticals A/S...
BioCentury | Apr 23, 2012
Company News

Enkam management update

Enkam Pharmaceuticals A/S , Copenhagen, Denmark Business: Neurology, Cancer Hired: Stephen Rees as COO WIR Staff cancer Neurology...
BioCentury | Dec 19, 2011
Company News

Enkam, Forenap Pharma EURL, Lundbeck, Qualissima S.a.r.l neurology news

...Qualissima received €6 million ($8 million) from the EU's seventh Framework Program (FP7) to develop Enkam's...
...a stroke. Enkam said it is currently in discussions with potential pharma partners for FGLs. Enkam Pharmaceuticals A/S...
BioCentury | Jun 25, 2009
Cover Story

Low-Rhes approach to Huntington's

...Inc. (NYSE-A:COR) CX929 An ampakine that is a positive modulator of AMPA glutamate receptors Preclinical Enkam Pharmaceuticals A/S...
BioCentury | Apr 16, 2009
Distillery Therapeutics

Indication: Neurology

...stem cells in preclinical testing to treat amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Enkam Pharmaceuticals A/S's...
BioCentury | Jan 21, 2008
Clinical News

Enkam preclinical data

...I trial of the neural cell adhesion molecule (NCAM) mimicking peptide will begin this year. Enkam Pharmaceuticals A/S...
BioCentury | Dec 11, 2006
Company News

Enkam, CHDI Inc. deal

...CHDI, a not-for-profit organization focused on Huntington's disease (HD), will provide Enkam with an undisclosed amount...
...the fibroblast growth factor (FGF) receptor . Enkam will retain all rights to the compounds. Enkam Pharmaceuticals A/S...
BioCentury | Sep 11, 2006
Tools & Techniques

Blocking beta cell destruction

...failure," Vladimir Berezin of the Institute of Molecular Pathology and CSO of Enkam Pharmaceuticals A/S told BioCentury. Enkam...
...anti-cancer molecules, has identified C3d, an NCAM-targeting peptide, as having potential to protect beta cells. Enkam...
BioCentury | Sep 11, 2006
Clinical News

Enkam preclinical data

...interleuekin 1 beta-induced MAP kinase activity and beta cell apoptosis. Data were published in Diabetologia. Enkam Pharmaceuticals A/S...
BioCentury | Jul 17, 2006
Clinical News

Enkam preclinical data

...cell activation in healthy rats. Data were presented at the European Neuroscience meeting in Vienna. Enkam Pharmaceuticals A/S...
Items per page:
1 - 10 of 14
BioCentury | Aug 22, 2013
Targets & Mechanisms

Tamping down TAU

...when massive and irreversible brain damage and spreading have already occurred. Morten Albrechtsen, CEO at Enkam Pharmaceuticals A/S...
...determining whether they will be effective at preventing disease, stopping its progression or curing patients. Enkam...
...Institutions Mentioned BioArctic Neuroscience AB , Stockholm, Sweden Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Enkam Pharmaceuticals A/S...
BioCentury | Apr 23, 2012
Company News

Enkam management update

Enkam Pharmaceuticals A/S , Copenhagen, Denmark Business: Neurology, Cancer Hired: Stephen Rees as COO WIR Staff cancer Neurology...
BioCentury | Dec 19, 2011
Company News

Enkam, Forenap Pharma EURL, Lundbeck, Qualissima S.a.r.l neurology news

...Qualissima received €6 million ($8 million) from the EU's seventh Framework Program (FP7) to develop Enkam's...
...a stroke. Enkam said it is currently in discussions with potential pharma partners for FGLs. Enkam Pharmaceuticals A/S...
BioCentury | Jun 25, 2009
Cover Story

Low-Rhes approach to Huntington's

...Inc. (NYSE-A:COR) CX929 An ampakine that is a positive modulator of AMPA glutamate receptors Preclinical Enkam Pharmaceuticals A/S...
BioCentury | Apr 16, 2009
Distillery Therapeutics

Indication: Neurology

...stem cells in preclinical testing to treat amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Enkam Pharmaceuticals A/S's...
BioCentury | Jan 21, 2008
Clinical News

Enkam preclinical data

...I trial of the neural cell adhesion molecule (NCAM) mimicking peptide will begin this year. Enkam Pharmaceuticals A/S...
BioCentury | Dec 11, 2006
Company News

Enkam, CHDI Inc. deal

...CHDI, a not-for-profit organization focused on Huntington's disease (HD), will provide Enkam with an undisclosed amount...
...the fibroblast growth factor (FGF) receptor . Enkam will retain all rights to the compounds. Enkam Pharmaceuticals A/S...
BioCentury | Sep 11, 2006
Tools & Techniques

Blocking beta cell destruction

...failure," Vladimir Berezin of the Institute of Molecular Pathology and CSO of Enkam Pharmaceuticals A/S told BioCentury. Enkam...
...anti-cancer molecules, has identified C3d, an NCAM-targeting peptide, as having potential to protect beta cells. Enkam...
BioCentury | Sep 11, 2006
Clinical News

Enkam preclinical data

...interleuekin 1 beta-induced MAP kinase activity and beta cell apoptosis. Data were published in Diabetologia. Enkam Pharmaceuticals A/S...
BioCentury | Jul 17, 2006
Clinical News

Enkam preclinical data

...cell activation in healthy rats. Data were presented at the European Neuroscience meeting in Vienna. Enkam Pharmaceuticals A/S...
Items per page:
1 - 10 of 14